- Press Releases
- Notices
Press Releases To List
-
- Dec.10.2024R & D
- SK Biopharmaceuticals’ Cenobamate Demonstrates Clinical Efficacy and Safety in Epilepsy Patients across Korea, China and Japan
-
- Dec.03.2024Licensing
- Ono Enters into Drug Discovery Collaboration Agreement with Congruence Therapeutics to Generate Novel Small Molecule Correctors in the Oncology Area
-
- Nov.18.2024R & D
- Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
-
- Oct.31.2024Management / Finance
- Revisions of Consolidated Financial Forecasts and Introduction of Core Basis in Financial Results
-
- Oct.31.2024Management / Finance
- Announcement on Financial Results for FY2024 Q2
Notices To List
-
- Oct.01.2024Corporate
- ONO begins Airing New Commercial “Rising to the challenges of Immuno-Oncology” in Japan
-
- Sep.30.2024Corporate
- Corporate Report 2024 has been released.
-
- Jun.21.2024Corporate
- Voting Results (Extraordinary Report) of the 76th Ordinary General Shareholders’ Meeting
-
- Jun.20.2024Corporate
- Notice to Resolutions Passed at The 76th Ordinary General shareholders’ Meeting
-
- May.23.2024Corporate
- Notice to Convene the 76th Ordinary General Shareholders' Meeting
About
We Want to Deliver New Drugs
to the World with a Wish.
For more than 300 years since its foundation in 1717, working for people’s health.
Diseases still unconquered. Patients' wishes still unfulfilled.
ONO, with a wish to meet these medical needs, devotes all its efforts to drug discovery.
